The significance of Syndecan 1, a new marker for endothelial dysfunction, in cases of fetal growth retardation.
Oğuz Y, Ağaoğlu RT, Ulusoy CO, Kurt D, Özgürlük İ, Soysal Ç, Yılmaz Vural Z, Yakut Yücel K.

Soluble Endoglin and Syndecan-1 levels predicts the clinical outcome in COVID-19 patients.
Rajan R, Hanifah M, Mariappan V, Anand M, Balakrishna Pillai A.

CD9 co-operation with syndecan-1 is required for a major staphylococcal adhesion pathway.
Green LR, Issa R, Albaldi F, Urwin L, Thompson R, Khalid H, Turner CE, Ciani B, Partridge LJ, Monk PN., Free PMC Article

CLINICAL VALUE OF SYNDECAN-1 LEVELS IN TRAUMA BRAIN INJURY: A META-ANALYSIS.
Xie WW, Ding YJ, Bhandari S, Li H, Chen HS, Jin SW, Weng HX, Hao Y.

Syndecan-1: A Novel Diagnostic and Therapeutic Target in Liver Diseases.
Zhang X, Zhao Y, Liu L, He Y.

Neutrophil Extracellular Traps Are Induced by Coronavirus 2019 Disease-Positive Patient Plasma and Persist Longitudinally: A Possible Link to Endothelial Dysfunction as Measured by Syndecan-1.
Kelly EJ, Oliver MA, Carney BC, Kolachana S, Moffatt LT, Shupp JW.

SDC1 and ITGA2 as novel prognostic biomarkers for PDAC related to IPMN.
Zhang CL, Shen Q, Liu FD, Yang F, Gao MQ, Jiang XC, Li Y, Zhang XY, En GE, Pan X, Pang B., Free PMC Article

Binding of Trichinella spiralis C-type lectin with syndecan-1 on intestinal epithelial cells mediates larval invasion of intestinal epithelium.
Wang Z, Lu QQ, Weng MM, Li YL, Han LL, Song YY, Shi YL, Liu RD, Cui J, Wang ZQ., Free PMC Article

Overexpression in metastatic breast cancer supports Syndecan-1 as a marker of invasiveness and poor prognosis.
Cerbelli B, Pisano A, Pignataro MG, Pernazza A, Botticelli A, Carosi M, Costarelli L, Allegretti M, d'Amati G, Cordone I., Free PMC Article

Dynamic interplay between sortilin and syndecan-1 contributes to prostate cancer progression.
Lazniewska J, Li KL, Johnson IRD, Sorvina A, Logan JM, Martini C, Moore C, Ung BS, Karageorgos L, Hickey SM, Prabhakaran S, Heatlie JK, Brooks RD, Huzzell C, Warnock NI, Ward MP, Mohammed B, Tewari P, Martin C, O'Toole S, Edgerton LB, Bates M, Moretti P, Pitson SM, Selemidis S, Butler LM, O'Leary JJ, Brooks DA., Free PMC Article

The utility of syndecan-1 circulating levels as a biomarker in patients with previous or active COVID-19: a systematic review and meta-analysis.
Ghondaghsaz E, Khalaji A, Norouzi M, Fraser DD, Alilou S, Behnoush AH., Free PMC Article

The Heparan Sulfate Proteoglycan Syndecan-1 Triggers Breast Cancer Cell-Induced Coagulability by Induced Expression of Tissue Factor.
Hassan N, Bückreiß N, Efing J, Schulz-Fincke M, König P, Greve B, Bendas G, Götte M., Free PMC Article

Evaluation of Intrafollicular Syndecan 1, Glypican 3, and Spermidine Levels in Women with Diminished Ovarian Reserve.
Gokce S, Herkiloglu D, Cevik O, Turan V.

High expression of SDC1 in stromal cells is associated with good prognosis in colorectal cancer.
Li Z, He S, Liu J, Zhi X, Yang L, Zhang J, Zhao R, Zhang R, Li L, Wang W., Free PMC Article

C-Reactive Protein, Interleukin-6, Trimethylamine-N-Oxide, Syndecan-1, Nitric Oxide, and Tumor Necrosis Factor Receptor-1 in Heart Failure with Preserved Versus Reduced Ejection Fraction: a Meta-Analysis.
Gui XY, Rabkin SW.

Aberrant protein expression of Appl1, Sortilin and Syndecan-1 during the biological progression of prostate cancer.
Martini C, Logan JM, Sorvina A, Gordon C, Beck AR, S-Y Ung B, Caruso MC, Moore C, Hocking A, Johnson IRD, Li KL, Karageorgos L, Hopkins AM, Esterman AJ, Huzzell C, Brooks RD, Lazniewska J, Hickey SM, Bader C, Parkinson-Lawrence E, Weigert R, Sorich MJ, Tewari P, Martin C, O'Toole S, Bates M, Ward M, Mohammed B, Keegan H, Watson W, Prendergast S, Heffernan S, NiMhaolcatha S, O'Connor R, Malone V, Carter M, Ryan K, Brady N, Clarke A, Sokol F, Prabhakaran S, Stahl J, Klebe S, Samaratunga H, Delahunt B, Selemidis S, Moretti KL, Butler LM, O'Leary JJ, Brooks DA.

Syndecan 1 may slow the progression of subclinical atherosclerosis in patients with ankylosing spondylitis.
Yilmaz PD, Kadiyoran C, Goktepe MH, Akkubak Y, Icli A, Kucuk A.

Expression of syndecan-1 in different grades of oral squamous cell carcinoma: An immunohistochemical study.
Shetty PK, Gonsalves N, Desai D, Pandit S, Aradhya C, Shahid M, Shubhalakshmi, Shetty SJ.

The heparan sulphate proteoglycan Syndecan-1 (CD138) regulates tumour progression in a 3D model of ductal carcinoma in situ of the breast.
D'Arcy C, Zimmermann CC, Espinoza-Sanchez NA, Greve B, Schmidt A, Kiesel L, von Wahlde MK, Götte M.

miR-335-5p Targets SDC1 to Regulate the Progression of Breast Cancer.
Song G, Ma Y, Ma Y, Liu P, Hou L, Xu Z, Jiang J, Shen Y, Cao Y, Zhao Y.

Single cell RNA-seq reveals the CCL5/SDC1 receptor-ligand interaction between T cells and tumor cells in pancreatic cancer.
Chen K, Wang Y, Hou Y, Wang Q, Long D, Liu X, Tian X, Yang Y.

Syndecan-1 in liver pathophysiology.
Reszegi A, Tátrai P, Regős E, Kovalszky I, Baghy K.

Targeting syndecan-1: new opportunities in cancer therapy.
Yang Z, Chen S, Ying H, Yao W., Free PMC Article

Syndecan-1 and -4 influence Wnt signaling and cell migration in human breast cancers.
Pham SH, Pratt K, Okolicsanyi RK, Oikari LE, Yu C, Peall IW, Arif KT, Chalmers TA, Gyimesi M, Griffiths LR, Haupt LM.

Serum Syndecan-1: A Novel Biomarker for Pancreatic Ductal Adenocarcinoma.
Yablecovitch D, Ben-Horin S, Picard O, Yavzori M, Fudim E, Nadler M, Levy I, Sakhnini E, Lang A, Engel T, Lahav M, Saker T, Neuman S, Selinger L, Dvir R, Raitses-Gurevich M, Golan T, Laish I., Free PMC Article